24.2 C
New York
Thursday, June 11, 2026

Tag: sleep apnea

newssourceFORcompanyinformationcontent1marketreleases

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS),  a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

INSIDE INFORMATION
REGULATED INFORMATION

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Ignored and Undiagnosed: Sleep Apnea Threatens Women’s Cognitive Health

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing...

Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research®

The Sleep Apnea Devices Market presents robust growth opportunities, especially in regions like North America and Europe where awareness, infrastructure, and reimbursement support are strong. However, high device costs and poor compliance rates remain critical hurdles. For successful market entry, companies must focus on product affordability, user comfort, and telemedicine integration. Expanding into Asia-Pacific with scalable, portable, and AI-enabled diagnostic tools offers a high-potential growth avenue, given the rising healthcare penetration. Strategic partnerships with local providers and government awareness programs will be key to unlocking untapped markets and gaining competitive advantage. 
The Sleep Apnea Devices Market presents robust growth opportunities, especially in regions like North America and Europe where awareness, infrastructure, and reimbursement support are strong. However, high device costs and poor compliance rates remain critical hurdles. For successful market entry, companies must focus on product affordability, user comfort, and telemedicine integration. Expanding into Asia-Pacific with scalable, portable, and AI-enabled diagnostic tools offers a high-potential growth avenue, given the rising healthcare penetration. Strategic partnerships with local providers and government awareness programs will be key to unlocking untapped markets and gaining competitive advantage.

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

- A word from our sponsors -

spot_img
HomeTagsSleep apnea

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers